← Leaderboards
Anne Searls De Groot
Brown University
$25,973,418
Attributed
$26,370,154
Total exposure
30
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–22$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$37,335,914 · 30
FDA$1,999,984 · 1
By mechanism
U19$17,116,994 · 4
R01$9,040,714 · 3
R43$6,946,798 · 11
R21$2,492,660 · 6
U01$1,999,984 · 1
R44$1,474,236 · 1
Top collaborators
- Chris Bailey-Kellogg2 shared
- Karl E Griswold2 shared
- Leonard Moise1 shared
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsBaseEpitopesDesignUniversitiesVaccinesVaccine DevelopmentVaccine DesignIn VivoResearch PersonnelImmune ResponseIn VitroImmunogenicityT-LymphocyteImmunogenicAntigensResponseAntibodiesCollaborationsImmunologyPathogenT-Lymphocyte EpitopesLeadPeptides
Grant awards (87)
ISPRI-HCP: CHO protein impurity immunogenicity risk prediction for improving biosimilar product development and assessing product interchangeability$1,999,984
U01 · FY2022 · FD · contact PI
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine$1,123,469
R01 · FY2021 · AI · contact PI
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine$1,136,044
R01 · FY2020 · AI · contact PI
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine$1,148,204
R01 · FY2019 · AI · contact PI
GAA-ITEM: Personalizing the Prediction of Anti-therapeutic Antibody Response in Pompe Disease Patients$133,578
R43 · FY2019 · TR · contact PI
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine$1,150,251
R01 · FY2018 · AI · contact PI
Influenza vaccine immunity shaped by human-like influenza epitopes$191,875
R21 · FY2018 · AI · contact PI
GAA-ITEM: Personalizing the Prediction of Anti-therapeutic Antibody Response in Pompe Disease Patients$191,402
R43 · FY2018 · TR · contact PI
Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease$139,842
R43 · FY2018 · DK · contact PI
Vaccine Renaissance Conference at the Institute for Immunology and Informatics$8,000
R13 · FY2018 · AI · contact PI
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine$1,221,150
R01 · FY2017 · AI · contact PI
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza$290,546
R43 · FY2017 · AI · contact PI
Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease$177,020
R43 · FY2017 · DK · contact PI
Vaccine Renaissance Conference at the Institute for Immunology and Informatics$8,000
R13 · FY2017 · AI · contact PI
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza$300,000
R43 · FY2016 · AI · contact PI
Vaccine Renaissance Conference at the Institute for Immunology and Informatics$8,000
R13 · FY2016 · AI · contact PI
Vaccine Renaissance Conference at the Institute for Immunology and Informatics$8,000
R13 · FY2015 · AI · contact PI
Vaccine Renaissance Conference at the Institute for Immunology and Informatics$8,000
R13 · FY2014 · AI · contact PI
Translational Immunology Research and Accelerated [vaccine] Development (TRIAD)$2,366,785
U19 · FY2013 · AI · contact PI
Multi-intracellular Pathogen Epitope-based Vaccine$966,971
U19 · FY2013 · AI · contact PI
EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of$727,574
R44 · FY2013 · DK · contact PI
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A$376,351
R43 · FY2013 · HL · contact PI
Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease$300,000
R43 · FY2013 · AI · contact PI
Computationally optimized anti-staphylococcal biotherapeutics$238,613
R21 · FY2013 · AI
TRIAD Pilot Projects Core$236,148
U19 · FY2013 · AI · contact PI
TRIAD Administrative Core$216,495
U19 · FY2013 · AI · contact PI
Vaccine Renaissance Conference at the Institute for Immunology and Informatics$7,000
R13 · FY2013 · AI · contact PI
Translational Immunology Research and Accelerated [vaccine] Development (TRIAD)$2,490,625
U19 · FY2012 · AI · contact PI
Preclinical Studies of Tregitope Delivery and Mechanism of Action in T1D$746,662
R44 · FY2012 · DK · contact PI
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A$381,361
R43 · FY2012 · HL · contact PI
Multi-intracellular Pathogen Epitope-based Vaccine$310,021
U19 · FY2012 · AI · contact PI
TRIAD Administrative Core$301,413
U19 · FY2012 · AI · contact PI
Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease$300,000
R43 · FY2012 · AI · contact PI
TRIAD Pilot Projects Core$298,802
U19 · FY2012 · AI · contact PI
Novel H1N1 influenza protection via cross-reactive immunity$250,758
R21 · FY2012 · AI · contact PI
Computationally optimized anti-staphylococcal biotherapeutics$212,585
R21 · FY2012 · AI
Vaccine Renaissance Conference at the Institute for Immunology and Informatics$7,000
R13 · FY2012 · AI · contact PI
Translational Immunology Research and Accelerated [vaccine] Development (TRIAD)$2,510,904
U19 · FY2011 · AI · contact PI
TRIAD Pilot Projects Core$248,244
U19 · FY2011 · AI · contact PI
Novel H1N1 influenza protection via cross-reactive immunity$221,484
R21 · FY2011 · AI · contact PI
TRIAD Administrative Core$198,508
U19 · FY2011 · AI · contact PI
Multi-intracellular Pathogen Epitope-based Vaccine$177,188
U19 · FY2011 · AI · contact PI
Vaccine Renaissance Conference at the Institute for Immunology and Informatics$7,000
R13 · FY2011 · AI · contact PI
Translational Immunology Research and Accelerated [vaccine] Development (TRIAD)$2,564,398
U19 · FY2010 · AI · contact PI
Translational Immunology Research and Accelerated [vaccine] Development (TRIAD)$511,121
U19 · FY2010 · AI · contact PI
TRIAD Pilot Projects Core$252,010
U19 · FY2010 · AI · contact PI
Optimization of HIV vaccine subunit delivery$243,561
R21 · FY2010 · AI · contact PI
TRIAD Administrative Core$198,901
U19 · FY2010 · AI · contact PI
Multi-intracellular Pathogen Epitope-based Vaccine$188,051
U19 · FY2010 · AI · contact PI
Epitope-driven deimmunization of Factor VIII$173,764
R43 · FY2010 · HL · contact PI
Translational Immunology Research and Accelerated [vaccine] Development (TRIAD)$35,894
U19 · FY2010 · AI · contact PI
Translational Immunology Research and Accelerated [vaccine] Development (TRIAD)$2,486,017
U19 · FY2009 · AI · contact PI
Optimization of HIV vaccine subunit delivery$215,016
R21 · FY2009 · AI · contact PI
Optimization of HIV vaccine subunit delivery$202,138
R21 · FY2009 · AI · contact PI
Multi-intracellular Pathogen Epitope-based Vaccine$199,876
U19 · FY2009 · AI · contact PI
TRIAD Administrative Core$197,051
U19 · FY2009 · AI · contact PI
TRIAD Pilot Projects Core$161,571
U19 · FY2009 · AI · contact PI
T1D Tolerance Induction with Natural Treg Epitopes$106,439
R43 · FY2009 · DK · contact PI
T1D Tolerance Induction with Natural Treg Epitopes$493,560
R43 · FY2008 · DK · contact PI
Optimization of a Multivalent Tuberculosis Vaccine$285,475
R43 · FY2008 · AI · contact PI
Epitope-driven deimmunization of Factor VIII$264,446
R43 · FY2008 · HL · contact PI
Development of De-immunized Botulinum Neurotoxin Type A for Dystonia$183,750
R21 · FY2008 · NS · contact PI
Optimization of HIV vaccine subunit delivery$163,400
R21 · FY2008 · AI · contact PI
Optimization of a Multivalent Tuberculosis Vaccine$299,908
R43 · FY2007 · AI · contact PI
Epitope-driven deimmunization of Factor VIII$263,867
R43 · FY2007 · HL · contact PI
Development of De-immunized Botulinum Neurotoxin Type A for Dystonia$153,125
R21 · FY2007 · NS · contact PI
Novel Smallpox Vaccine Derived from VV/VAR Immunome$527,522
R43 · FY2006 · AI · contact PI
A Genome-Derived, Epitope-Driven H. Pylori Vaccine$309,787
R43 · FY2006 · AI · contact PI
Epitope Driven HIV Vaccine Development AI50528-01A1$39,372
R03 · FY2006 · TW · contact PI
2nd Annual Vaccine Renaissance Conference, RI$17,500
R13 · FY2006 · AI · contact PI
Novel Smallpox Vaccine Derived from VV/VAR Immunome$499,885
R43 · FY2005 · AI
A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE$410,485
R43 · FY2005 · AI
A Genome-Derived, Epitope-Driven H. Pylori Vaccine$300,123
R43 · FY2005 · AI
Epitope Driven HIV Vaccine Development$206,000
R01 · FY2005 · AI
Epitope Driven HIV Vaccine Development AI50528-01A1$28,085
R03 · FY2005 · TW
Epitope Driven HIV Vaccine Development AI50528-01A1$12,235
R03 · FY2005 · TW
Epitope Driven HIV Vaccine Development$1,090,484
R01 · FY2004 · AI
A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE$421,437
R43 · FY2004 · AI
Epitope Driven HIV Vaccine Development AI50528-01A1$40,320
R03 · FY2004 · TW
Epitope Driven HIV Vaccine Development$3,529
R01 · FY2004 · AI
Epitope Driven HIV Vaccine Development$916,902
R01 · FY2003 · AI
Epitope Driven HIV Vaccine Development$51,763
R01 · FY2003 · AI
Epitope Driven HIV Vaccine Development$698,286
R01 · FY2002 · AI
HIV-1/HIV-2 EPITOPE PROJECT, THE GAMBIA, WEST AFRICA$40,000
R03 · FY2001 · TW
HIV EVOLUTION AND CELLULAR IMMUNE RESPONSE$294,632
R01 · FY2000 · AI
A CROSS CLADE APPROACH TO HIV VACCINE DEVELOPMENT$216,355
R21 · FY2000 · AI
A GENOME DERIVED REVERSE IMMUNOGENETICS TB VACCINE$26,000
RC1 · FY2000 · AI